Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
GlobalData on MSN16h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Armed robbery in Revesby22h
EU Greenlights Galderma's Nemluvio for Skin Conditions
Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...
How to get rid of and prevent milia, according to derms
Though milia tends to go away on their own, the best treatments and prevention methods include retinoids and exfoliants. Shop ...
IFLScience on MSN12h
Red Light Therapy: Skincare Superhero Or Beauty Bust?
If you’ve ever seen a beauty influencer don one of those mildly creepy red light masks, you might have wondered if they ...
emjreviews.com20h
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
Too Old to Operate12h
Gaps in Burn Assessment Tools Affect Patients With Darker Skin
Research shows gaps in medical literature and clinical guidelines on burn injuries in darker skin may contribute to variations in care quality and outcomes.